Different Faces of Hepatocellular Carcinoma as a Health Threat in 21st Century

authors:

avatar Behzad Yeganeh 1 , avatar Mohammad Hashemi 2 , 3 , avatar Fredrick J. de Serres 4 , avatar Marek J. Los 5 , * , avatar Saeid Ghavami 1 , 6 , 7 , *

Department of Physiology, University of Manitoba, Winnipeg, Canada
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Center for Evaluation of Risks to Human Reproduction, National Institute of Environmental Health Sciences, Research Triangle Park, Chapel Hill, USA
Division of Cell Biology, Department of Clinical and Experimental Medicine, Integrative Regenerative Medicine Center (IGEN), Linköping University, Linköping, Sweden
Manitoba Institute of Child Health, Winnipeg, Canada
St. Boniface Research Centre, University of Manitoba, Winnipeg, Canada
Corresponding Authors:
Hepatitis Monthly: Vol.13, issue 2; e9308
published online: February 4, 2013
article type: Editorial
received: November 27, 2012
accepted: December 1, 2012
DOI: https://doi.org/10.5812/hepatmon.9308

how to cite: Yeganeh B, Hashemi M, J. de Serres F, J. Los M, Ghavami S. Different Faces of Hepatocellular Carcinoma as a Health Threat in 21st Century. Hepat Mon. 2013;13(2):e9308. https://doi.org/10.5812/hepatmon.9308.

Acknowledgements

References

  • 1.

    Hashemi M, Ghavami S. Hepatocellular recurrence after orthotopic liver transplantation: Is combination of alpha-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation. Hepat Mon. 2011;11(3):155-6. [PubMed ID: 22087135].

  • 2.

    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. [PubMed ID: 21296855]. https://doi.org/10.3322/caac.20107.

  • 3.

    Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30(1):3-16. [PubMed ID: 20175029]. https://doi.org/10.1055/s-0030-1247128.

  • 4.

    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-37. [PubMed ID: 18304676]. https://doi.org/10.1016/j.jhep.2008.01.022.

  • 5.

    Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC). e6122. [PubMed ID: 23162601].

  • 6.

    Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol. 1993;33(1):43-7. [PubMed ID: 8269588].

  • 7.

    McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs. 2001;10(1):119-28. [PubMed ID: 11116285]. https://doi.org/10.1517/13543784.10.1.119.

  • 8.

    Sternberg CN, de Mulder P, Fossa S, Kaye S, Roberts T, Pawinsky A, et al. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann Oncol. 1997;8(7):695-6. [PubMed ID: 9296225].

  • 9.

    Dai HY, Liu L, Qin SK, He XM, Li SY. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro. Biomed Pharmacother. 2011;65(3):137-41. [PubMed ID: 21612887]. https://doi.org/10.1016/j.biopha.2010.12.001.

  • 10.

    Gietema JA, Guchelaar HJ, de Vries EG, Aulenbacher P, Sleijfer DT, Mulder NH. A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs. 1993;4(1):51-5. [PubMed ID: 8457715].

  • 11.

    Wang Z, Tang X, Zhang Y, Qi R, Li Z, Zhang K, et al. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE. Biomed Pharmacother. 2012;66(3):161-6. [PubMed ID: 22425181]. https://doi.org/10.1016/j.biopha.2011.09.008.

  • 12.

    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. [PubMed ID: 15761078].

  • 13.

    Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2011;26(6):960-4. [PubMed ID: 21443660]. https://doi.org/10.1111/j.1440-1746.2011.06723.x.

  • 14.

    Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol. 2000;95(5):1316-22. [PubMed ID: 10811346].

  • 15.

    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6-9. [PubMed ID: 16352363]. https://doi.org/10.1016/j.jhep.2005.11.004.

  • 16.

    Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593-601. [PubMed ID: 15802978].

  • 17.

    Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61 Suppl 1:i47-58. [PubMed ID: 22504919]. https://doi.org/10.1136/gutjnl-2012-302062.

  • 18.

    Zidan A, Scheuerlein H, Schule S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12(10 HCC). e6894. [PubMed ID: 23233864]. https://doi.org/10.5812/hepatmon.6894.

  • 19.

    Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon. 2012;12(10 HCC). e7635. [PubMed ID: 23233865]. https://doi.org/10.5812/hepatmon.7635.

  • 20.

    Kew MC. Hepatitis B virus / human immunodeficiency virus co-infection and its hepatocarcinogenic potential in sub-saharan black africans. Hepat Mon. 2012;12(10 HCC). e7876. [PubMed ID: 23166538]. https://doi.org/10.5812/hepatmon.7876.

  • 21.

    Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg. 2012;397(5):681-95. [PubMed ID: 22290218]. https://doi.org/10.1007/s00423-012-0911-2.

  • 22.

    Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12(10 HCC). e6031. [PubMed ID: 23166535]. https://doi.org/10.5812/hepatmon.6031.

  • 23.

    Hashemi M, Alavian SM, Ghavami S, de Serres FJ, Salehi M, Doroudi T, et al. High prevalence of alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran. Hepatol Res. 2005;33(4):292-7. [PubMed ID: 16260177]. https://doi.org/10.1016/j.hepres.2005.09.035.

  • 24.

    Hashemi M, Naderi M, Rashidi H, Ghavami S. Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract. 2007;75(2):246-8. [PubMed ID: 16875754]. https://doi.org/10.1016/j.diabres.2006.06.020.

  • 25.

    Lee P, Gildea TR, Stoller JK. Emphysema in nonsmokers: alpha 1-antitrypsin deficiency and other causes. Cleve Clin J Med. 2002;69(12):928-9. [PubMed ID: 12546267].

  • 26.

    de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64(5):382-97. [PubMed ID: 14616761].

  • 27.

    de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain. Clin Genet. 2003;63(6):490-509. [PubMed ID: 12786756].

  • 28.

    Topic A, Ljujic M, Radojkovic D. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC). e7042. [PubMed ID: 23162602]. https://doi.org/10.5812/hepatmon.7042.

  • 29.

    Blanco I, de Serres FJ, Carcaba V, Lara B, Fernandez-Bustillo E. Alpha-1 Antitrypsin Deficiency PI*Z and PI*S Gene Frequency Distribution Using on Maps of the World by an Inverse Distance Weighting (IDW) Multivariate Interpolation Method. Hepat Mon. 2012;12(10 HCC). e7434. [PubMed ID: 23166537]. https://doi.org/10.5812/hepatmon.7434.

  • 30.

    Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 2009;625(1-3):73-83. [PubMed ID: 19835859]. https://doi.org/10.1016/j.ejphar.2009.08.044.

  • 31.

    Halayko AJ, Ghavami S. S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol. 2009;87(10):743-55. [PubMed ID: 19898558]. https://doi.org/10.1139/Y09-054.

  • 32.

    Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, et al. S100A8/A9 induces autophagy and apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res. 2010;20(3):314-31. [PubMed ID: 19935772]. https://doi.org/10.1038/cr.2009.129.

  • 33.

    Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, Zuse A, et al. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta. 2008;1783(2):297-311. [PubMed ID: 18060880]. https://doi.org/10.1016/j.bbamcr.2007.10.015.

  • 34.

    Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181(7):4666-75. [PubMed ID: 18802069].

  • 35.

    Maletzki C, Bodammer P, Breitruck A, Kerkhoff C. S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC). e7240. [PubMed ID: 23166536]. https://doi.org/10.5812/hepatmon.7240.

  • 36.

    Kim HR, Kim TW. Occupational hepatic disorders in Korea. J Korean Med Sci. 2010;25(Suppl):S36-40. [PubMed ID: 21258588]. https://doi.org/10.3346/jkms.2010.25.S.S36.

  • 37.

    Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166-76. [PubMed ID: 17401425]. https://doi.org/10.1038/sj.onc.1210279.

  • 38.

    Uccello M, Malaguarnera G, Corriere T, Biondi A, Basile F, Malaguarnera M. Risk of hepatocellular carcinoma in workers exposed to chemicals. Hepat Mon. 2012;12(10 HCC). e5943. [PubMed ID: 23162599]. https://doi.org/10.5812/hepatmon.5943.

  • 39.

    Wogan GN, Newberne PM. Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. Cancer Res. 1967;27(12):2370-6. [PubMed ID: 4295478].

  • 40.

    Wu HC, Santella R. The role of aflatoxins in hepatocellular carcinoma. Hepat Mon. 2012;12(10 HCC). e7238. [PubMed ID: 23162603]. https://doi.org/10.5812/hepatmon.7238.

  • 41.

    Tazuma S. Gallstone disease: Epidemiology, pathogenesis, and classification of biliary stones (common bile duct and intrahepatic). Best Pract Res Clin Gastroenterol. 2006;20(6):1075-83. [PubMed ID: 17127189]. https://doi.org/10.1016/j.bpg.2006.05.009.

  • 42.

    Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1485-92. [PubMed ID: 20796144]. https://doi.org/10.1111/j.1440-1746.2010.06430.x.

  • 43.

    Al Hamoudi W, Khalaf H, Allam N, Al Sebayel M. Coincidental occurrence of hepatocellular carcinoma and cholangiocarcinoma (collision tumors) after liver transplantation: a case report. Hepat Mon. 2012;12(10 HCC). e5871. [PubMed ID: 23162598]. https://doi.org/10.5812/hepatmon.5871.

  • 44.

    Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007;27(2):155-62. [PubMed ID: 17311609]. https://doi.org/10.1111/j.1478-3231.2006.01409.x.

  • 45.

    Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, et al. The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon. 2012;12(10 HCC). e7492. [PubMed ID: 23162604]. https://doi.org/10.5812/hepatmon.7492.

  • 46.

    Izumi N. Recent advances of radiofrequency ablation for early hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26 Suppl 1:115-22. [PubMed ID: 21199522]. https://doi.org/10.1111/j.1440-1746.2010.06543.x.